ALK and non-small cell lung carcinoma: Screening for anaplastic lymphoma kinase (ALK) gene rearrangements is an important aspect of management of NSCLC, demonstrated by those who tested positive and treated with tyrosine kinase inhibitors (TKI) in an Aotearoa New Zealand-based study having markedly improved survival rates and times (although not analyzed by ethnicity) [17].